Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics, facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that is currently in Phase II testing; and LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth and has completed an end-of-Phase II meeting with the Food and Drug Administration. Lipocine Inc. is headquartered in Salt Lake City, Utah.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LPCN
CUSIPN/A
Phone801-994-7383
Debt
Debt-to-Equity Ratio0.52
Current Ratio5.03
Quick Ratio5.04
Price-To-Earnings
Trailing P/E Ratio-1.30
Forward P/E Ratio-1.53
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.89 per share
Price / Book1.52
Profitability
EPS (Most Recent Fiscal Year)($1.05)
Net Income$-20,980,000.00
Net MarginsN/A
Return on Equity-89.14%
Return on Assets-67.72%
Miscellaneous
Employees14
Outstanding Shares21,260,000
Lipocine (NASDAQ:LPCN) Frequently Asked Questions
What is Lipocine's stock symbol?
Lipocine trades on the NASDAQ under the ticker symbol "LPCN."
How were Lipocine's earnings last quarter?
Lipocine Inc (NASDAQ:LPCN) posted its quarterly earnings results on Monday, May, 7th. The specialty pharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.21) by $0.08. The specialty pharmaceutical company had revenue of $0.43 million for the quarter. View Lipocine's Earnings History.
When is Lipocine's next earnings date?
What price target have analysts set for LPCN?
5 brokers have issued 12-month price objectives for Lipocine's shares. Their forecasts range from $2.00 to $38.00. On average, they expect Lipocine's share price to reach $12.80 in the next year. View Analyst Ratings for Lipocine.
Who are some of Lipocine's key competitors?
Some companies that are related to Lipocine include Sophiris Bio (SPHS), Aptevo Therapeutics (APVO), Ophthotech (OPHT), Scpharmaceuticals (SCPH), Catalyst Biosciences (CBIO), Recro Pharma (REPH), Proteostasis Therapeutics (PTI), Sesen Bio (SESN), Oramed Pharmaceuticals (ORMP), Oncolytics Biotech (ONCYF), BIOLINERX Ltd/S (BLRX), Gemphire Therapeutics (GEMP), Genprex (GNPX), Aerpio Pharmaceuticals (ARPO) and CytoDyn (CYDY).
Who are Lipocine's key executives?
Lipocine's management team includes the folowing people:
- Dr. Mahesh V. Patel Ph.D., Co-Founder, Chairman, Pres & CEO (Age 61)
- Mr. Morgan R. Brown MBA, CPA, Exec. VP, CFO & Corp. Sec. (Age 50)
- Dr. William I. Higuchi Ph.D., Chief Scientific Consultant (Age 87)
- Logan Morse, VP of Marketing and Sales Operations
- Dr. Anthony DelConte M. D., Chief Medical Director (Age 60)
Has Lipocine been receiving favorable news coverage?
Headlines about LPCN stock have been trending somewhat positive this week, according to Accern. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Lipocine earned a news sentiment score of 0.13 on Accern's scale. They also assigned news stories about the specialty pharmaceutical company an impact score of 47.17 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Lipocine?
Shares of LPCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lipocine's stock price today?
One share of LPCN stock can currently be purchased for approximately $1.35.
How big of a company is Lipocine?
Lipocine has a market capitalization of $28.39 million. The specialty pharmaceutical company earns $-20,980,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. Lipocine employs 14 workers across the globe.
How can I contact Lipocine?
Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The specialty pharmaceutical company can be reached via phone at 801-994-7383 or via email at [email protected]
MarketBeat Community Rating for Lipocine (LPCN)
MarketBeat's community ratings are surveys of what our community members think about Lipocine and other stocks. Vote "Outperform" if you believe LPCN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPCN will underperform the S&P 500 over the long term. You may vote once every thirty days.
